Evidence map›Paper›PMID 42204028›Full record

ArticleThe AAPS journal2026

Development and Implementation of a Hinderance-based In Vitro Model for Porous Membranes.

Daniel A Paterson, Lucy Coleman, Yuri Dancik, Kanika Thakur, Yanling Zhang, Alice Maciel Tabosa, Sebastian Polak, James F Clarke

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniel A PatersonCertara Predictive Technologies Division, Certara UK Ltd., Level 2-Acero 1 Concourse Way, Sheffield, S1 2BJ, UK.ORCID 0000-0001-7170-8266
Lucy ColemanCertara Predictive Technologies Division, Certara UK Ltd., Level 2-Acero 1 Concourse Way, Sheffield, S1 2BJ, UK. lucy.coleman@certara.com.ORCID 0000-0001-9036-1317
Yuri DancikCertara Predictive Technologies Division, Certara UK Ltd., Level 2-Acero 1 Concourse Way, Sheffield, S1 2BJ, UK.ORCID 0000-0002-3652-9673
Kanika ThakurCertara Predictive Technologies Division, Certara UK Ltd., Level 2-Acero 1 Concourse Way, Sheffield, S1 2BJ, UK.ORCID 0009-0005-3550-5126
Yanling ZhangCertara Predictive Technologies Division, Certara UK Ltd., Level 2-Acero 1 Concourse Way, Sheffield, S1 2BJ, UK.ORCID 0000-0001-9303-2498
Alice Maciel TabosaCertara Predictive Technologies Division, Certara UK Ltd., Level 2-Acero 1 Concourse Way, Sheffield, S1 2BJ, UK.ORCID 0000-0003-3926-8349
Sebastian PolakCertara Predictive Technologies Division, Certara UK Ltd., Level 2-Acero 1 Concourse Way, Sheffield, S1 2BJ, UK.ORCID 0000-0001-8614-0642
James F ClarkeCertara Predictive Technologies Division, Certara UK Ltd., Level 2-Acero 1 Concourse Way, Sheffield, S1 2BJ, UK.ORCID 0000-0002-9417-4567

Funding

FDA HHS U01 FD007323
6 · The paper itself

Abstract

In vitro release testing (IVRT) is an inexpensive and routine step in dermal formulation development where an inert membrane separates the donor formulation from a receptor solution. Experimental IVRT data provides insights into formulation behaviour in the absence of skin permeation complexities. This source of formulation data has the potential to be incorporated into a modelling workflow to aid parameterisation of a mechanistic dermal physiologically based pharmacokinetic (PBPK) model. Therefore, a hinderance-based IVRT model was developed within the Simcyp in vitro permeation testing (IVPT) module framework, using membrane characteristics to inform drug movement through inert, non-silicone, membranes. Modelling as a cylindrical pore system, the membranes key characteristics (pore size, porosity, tortuosity and membrane thickness) are utilised to parameterise a 2-step model where drug enters the membrane pores, diffuses across and partitions into the receptor solution. A description of the model's equations and setup are provided in addition to an ibuprofen in vitro case study using a range of membranes for model performance validation. Comparison of simulated IVRT to experimental data using membranes of microfiltration (pore diameters > 0.1 µm) resulted in acceptable performance, while simulation of nanofiltration membranes (pore diameters < 0.01 µm) require optimisation steps.

Indexed as

Membranes, ArtificialModels, BiologicalAdministration, CutaneousChemistry, PharmaceuticalDrug LiberationHumansIbuprofenPermeabilityPorositySkin AbsorptionIbuprofenMembranes, Artificialgeneric membraneibuprofenin vitro release testingmodelling

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.